Patents by Inventor Daniel A. Heller

Daniel A. Heller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240071566
    Abstract: Disclosed are approaches to acquiring a “disease fingerprint” from biosamples by collecting large data sets of physicochemical interactions to a sensor array composed of organic color center-modified carbon nanotubes. Array responses from subjects may be used to train and validate machine learning models to differentiate diseases and healthy individuals. The trained learning models may be used to subsequently classify patients based on nanosensor array emission data.
    Type: Application
    Filed: January 20, 2022
    Publication date: February 29, 2024
    Inventors: Daniel A. HELLER, Mijin KIM, Yoona YANG, Yuhuang WANG, Anand JAGOTA, Ming ZHENG
  • Publication number: 20240009359
    Abstract: Described herein are medical apparatuses, formulations, manufacturing processes, and medical procedures relating to drug eluting rubber bands that may be used for banding procedures such as hemorrhoid ligation. Examples of therapeutic agents that can be eluted for therapeutic effect include local anesthetics, opioids, calcium channel blockers, antibiotics, sclerosing agents, and steroids.
    Type: Application
    Filed: August 30, 2021
    Publication date: January 11, 2024
    Inventors: Ron Feiner, Takeshi Irie, Daniel A. Heller
  • Publication number: 20230114946
    Abstract: A drug carrier nanoparticle has been synthesized that can specifically target the proximal tubules of the kidneys. The nanoparticles accumulate in the kidneys to a greater extent than other organs (e.g., up to 3 or more times greater in the kidney than any other organ). They can encapsulate many classes of drug molecules. The nanoparticles are biodegradable and release the drug as they degrade. The particles can sustainably release a drug within the kidneys for up to two months. The nanoparticles are useful for the treatment of diseases that affect the proximal tubules, such as heart failure, liver cirrhosis, hypertension, and renal failure; the study of relative blood flow to the renal cortex and medulla; and delivery of agents to treat gout.
    Type: Application
    Filed: May 20, 2022
    Publication date: April 13, 2023
    Inventors: Daniel A. HELLER, Ryan M. WILLIAMS
  • Patent number: 11605246
    Abstract: A computing system receives location data from a computing device of a transport provider and based on the location data, monitors a location of the transport provider as the transport provider operates a vehicle to travel towards a service location of the service request. The system determines, based on monitoring the location of the transport provider, that the transport provider has not indicated at least one of a correct start location or a correct start time for fulfilling the service request. In response to determining that the transport provider has not indicated the at least one of the correct start location or the correct start time, the system uses a set of the location data received from the computing device of the transport provider to determine the at least one of the correct start location or the correct start time for fulfilling the service request.
    Type: Grant
    Filed: July 8, 2021
    Date of Patent: March 14, 2023
    Assignee: Uber Technologies, Inc.
    Inventors: Kevin Brinig, Daniel Heller, Todd Sifleet, Jyothidhar Pulakunta
  • Publication number: 20220276171
    Abstract: A method of detecting a condition in a subject comprises the steps of contacting cells of the subject with single-walled carbon nanotubes (SWCNTs), monitoring photoluminescence emitted by SWCNTs internalized into the cells and generating an SW-CNT emission profile, comparing the SWCNT emission profile to a control emission profile for the SWCNTs to produce a result, and determining a likelihood of having the condition in the subject based on the result from the comparing step. Also disclosed is a method for screening agents capable of changing endocytic environment using SWCNTs.
    Type: Application
    Filed: October 8, 2021
    Publication date: September 1, 2022
    Inventors: Prakrit JENA, Daniel A. HELLER, Daniel ROXBURY
  • Publication number: 20220257599
    Abstract: The present technology is directed to methods useful in treating cancer, slowing growth of a tumor, reversing growth of a tumor, slowing growth of a neoplasm, reversing growth of a neoplasm, slowing proliferation of a neoplasm, and/or reversing proliferation of a neoplasm, for cancers, tumors, and neoplasms harboring a constitutively active variant of one or both of KRAS or HRAS, where the constitutively active variant is a gain of function mutation, a duplication, or a gene amplification.
    Type: Application
    Filed: July 15, 2020
    Publication date: August 18, 2022
    Inventors: Daniel HELLER, Christopher HOROSZKO
  • Patent number: 11255848
    Abstract: A composition can include a complex, where the complex includes a photoluminescent nanostructure and a polymer free from selective binding to an analyte, the polymer adsorbed on the photoluminescent nanostructure, and a selective binding site associated with the complex.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 22, 2022
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Michael S. Strano, Jingqing Zhang, Paul Walter Barone, Daniel A. Heller, Jong-Ho Kim
  • Publication number: 20210364507
    Abstract: Described herein are compositions useful for the detection of analytes. In certain embodiments, the invention relates among other things to DNA-encapsulated single-walled carbon nanotubes (SWCNTs) functionalized with an antibody or other analyte-binding species, for detection and/or imaging of an analyte in a biological sample or subject. Other embodiments described herein include systems, methods, and devices utilizing such compositions for ex vivo biomarker quantification, tissue optical probes, and in vivo analyte detection and quantification. In one aspect the invention relates to a single-walled carbon nanotube (SWCNT) sensor, comprising a SWCNT; a polymer associated with the SWCNT; and an analyte-binding species. Detection of one or more analytes is achieved by measuring changes in fluorescence intensity, shifts in fluorescence wavelength, and/or other characteristics in the spectral characteristics of the described compositions.
    Type: Application
    Filed: August 4, 2021
    Publication date: November 25, 2021
    Inventors: Daniel A. Heller, Ryan M. Williams
  • Publication number: 20210335056
    Abstract: A computing system receives location data from a computing device of a transport provider and based on the location data, monitors a location of the transport provider as the transport provider operates a vehicle to travel towards a service location of the service request. The system determines, based on monitoring the location of the transport provider, that the transport provider has not indicated at least one of a correct start location or a correct start time for fulfilling the service request. In response to determining that the transport provider has not indicated the at least one of the correct start location or the correct start time, the system uses a set of the location data received from the computing device of the transport provider to determine the at least one of the correct start location or the correct start time for fulfilling the service request.
    Type: Application
    Filed: July 8, 2021
    Publication date: October 28, 2021
    Inventors: Kevin Brinig, Daniel Heller, Todd Sifleet, Jyothidhar Pulakunta
  • Publication number: 20210262017
    Abstract: Described herein are novel devices and methods for the optical detection of oligonucleotide binding events for diagnostic, point-of-care, drug screening, and theranostic applications, for example, a robust and customizable system to detect specific DNA and RNA oligonucleotides using a carbon nanotube optical signal.
    Type: Application
    Filed: August 20, 2020
    Publication date: August 26, 2021
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Jackson HARVEY, Daniel HELLER, Prakrit JENA
  • Patent number: 11097019
    Abstract: Described herein are suspensions of helical polycarbodiimide polymers that ‘cloak’ nanotubes, thereby effecting control over nanotube emission, providing a new mechanism of environmental responsivity, and enabling precise control over sub-cellular localization. The helical polycarbodiimide polymers described herein are water soluble, easily modifiable, and have unique architectures that facilitate their application in radiopharmaceutical delivery and imaging methods, in therapeutics and therapeutic delivery methods, and their use as sensors—both in conjunction with carbon nanotubes, and without nanotubes.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: August 24, 2021
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Daniel Heller, Januka Budhathoki-Uprety
  • Patent number: 11098348
    Abstract: Disclosed herein are methods and compositions for detection of target polynucleotides in a mixed sample by amplification of the target polynucleotide and detection in a nanopore device.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: August 24, 2021
    Assignee: Ontera Inc.
    Inventors: Trevor J. Morin, Tyler Shropshire, William B. Dunbar, Daniel A. Heller, Hongyun Wang
  • Patent number: 11080944
    Abstract: A computer system can communicate with a mobile device of a service provider to receive location data. Additionally, the computer system can monitor, from the location data, a location of the mobile device over a duration that follows the service provider being assigned to a service request. Based on monitoring the location data, the computer system can determine whether the service provider has failed to correctly indicate when a transport service for the service request began. Moreover, the computer system can cause a service application running on the mobile device to prompt the service provider to enter input to identify a start location where the transport service began, in response to the computer system determining that the service provider has not correctly indicated when the transport service begun.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: August 3, 2021
    Assignee: UBER TECHNOLOGIES, INC.
    Inventors: Kevin Brinig, Daniel Heller, Todd Sifleet, Jyothidhar Pulakunta
  • Publication number: 20200237670
    Abstract: Described herein are nanoparticles which are largely made of (e.g., 90 wt. %) hydrophobic drugs and are stabilized by water soluble dyes. The nanoparticles can range in size from 30 nm to 150 nm and have highly negative surface charge (e.g., ?55 mV). These nanoparticles are highly soluble in water, stable for days in PBS buffer and can be easily lyophilzed and reconstituted in water. Using quantitative self-assembly prediction calculations, topochemical molecular descriptors were identified and validated as highly predictive indicators of nano-assembly, nanoparticle size, and drug loading. The resulting nanoparticles selectively targeted kinase inhibitors to caveolin-1expressing human colon cancer and autochthonous liver cancer models to yield striking therapeutic effects while avoiding pERK inhibition in healthy skin. The nanoparticles exhibited remarkable anti-tumor efficacy in vitro and in vivo in models of hepatocellular carcinoma.
    Type: Application
    Filed: November 27, 2019
    Publication date: July 30, 2020
    Inventors: Daniel A. HELLER, Yosef SHAMAY
  • Publication number: 20200222333
    Abstract: A drug carrier nanoparticle has been synthesized that can specifically target the proximal tubules of the kidneys. The nanoparticles accumulate in the kidneys to a greater extent than other organs (e.g., up to 3 or more times greater in the kidney than any other organ). They can encapsulate many classes of drug molecules. The nanoparticles are biodegradable and release the drug as they degrade. The particles can sustainably release a drug within the kidneys for up to two months. The nanoparticles are useful for the treatment of diseases that affect the proximal tubules, such as heart failure, liver cirrhosis, hypertension, and renal failure; the study of relative blood flow to the renal cortex and medulla; and delivery of agents to treat gout.
    Type: Application
    Filed: September 20, 2019
    Publication date: July 16, 2020
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Daniel A. HELLER, Ryan M. WILLIAMS
  • Publication number: 20200074752
    Abstract: A computer system can communicate with a mobile device of a service provider to receive location data. Additionally, the computer system can monitor, from the location data, a location of the mobile device over a duration that follows the service provider being assigned to a service request. Based on monitoring the location data, the computer system can determine whether the service provider has failed to correctly indicate when a transport service for the service request began. Moreover, the computer system can cause a service application running on the mobile device to prompt the service provider to enter input to identify a start location where the transport service began, in response to the computer system determining that the service provider has not correctly indicated when the transport service begun.
    Type: Application
    Filed: November 6, 2019
    Publication date: March 5, 2020
    Inventors: Kevin Brinig, Daniel Heller, Todd Sifleet, Jyothidhar Pulakunta
  • Publication number: 20190383744
    Abstract: A method of detecting a condition in a subject comprises the steps of contacting cells of the subject with single-walled carbon nanotubes (SWCNTs), monitoring photoluminescence emitted by SWCNTs internalized into the cells and generating an SWCNT emission profile, comparing the SWCNT emission profile to a control emission profile for the SWCNTs to produce a result, and determining a likelihood of having the condition in the subject based on the result from the comparing step. Also disclosed is a method for screening agents capable of changing endocytic environment using SWCNTs.
    Type: Application
    Filed: August 22, 2019
    Publication date: December 19, 2019
    Inventors: Prakrit JENA, Daniel A. HELLER, Daniel ROXBURY
  • Publication number: 20190374661
    Abstract: Described herein are suspensions of helical polycarbodiimide polymers that ‘cloak’ nanotubes, thereby effecting control over nanotube emission, providing a new mechanism of environmental responsivity, and enabling precise control over sub-cellular localization. The helical polycarbodiimide polymers described herein are water soluble, easily modifiable, and have unique architectures that facilitate their application in radiopharmaceutical delivery and imaging methods, in therapeutics and therapeutic delivery methods, and their use as sensors—both in conjunction with carbon nanotubes, and without nanotubes.
    Type: Application
    Filed: December 31, 2018
    Publication date: December 12, 2019
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Daniel HELLER, Januka BUDHATHOKI-UPRETY
  • Patent number: 10482684
    Abstract: A system for programmatically determining location information in connection with a transport service is disclosed. A driver can operate a driver device and can be assigned to provide a transport service for a user. Based on the current location of the driver device with respect to the pickup location for the user, and based on when the driver provides input indicating that the transport service has begun, the system can identify a previous location of the driver device as a start location of the transport service.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: November 19, 2019
    Assignee: Uber Technologies, Inc.
    Inventors: Kevin Brinig, Daniel Heller, Todd Sifleet, Jyothidhar Pulakunta
  • Patent number: 10478506
    Abstract: Described herein are polymeric drug-carrying nanogels that are capable of targeting to P-selectin for the treatment of cancer and other diseases and conditions associated with P-selectin. Furthermore, in certain embodiments, the nanogels presented here offer a drug release mechanism based on acidic pH in the microenvironment of a tumor, thereby providing improved treatment targeting capability and allowing use of lower drug doses, thereby reducing toxicity.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: November 19, 2019
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Adriana Haimovitz-Friedman, Daniel A. Heller, Yosef Shamay